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Abstract
Introduction: Perinatal hypoxic–ischemic (HI) encephalopathy is deﬁned as a neurological syndrome where the
newborn suffers from acute ischemia and hypoxia during the perinatal period. New therapies are needed. The acy-
lethanolamides, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), possess neuroprotective properties,
and they could be effective against perinatal HI. These lipid mediators act through peroxisome proliferator-activated
receptors subtype a (PPARa), or transient receptor potential vanilloid (TRPV), such as TRPV subtype 1 and 4.
Materials and Methods: The objectives of this study were to discern: (1) the neuroprotective role of OEA and
PEA in parietotemporal cortical neurons of newborn rats and mice subjected to hypoxia, and (2) the role of the
receptors, PPARa, TRPV1, and TRPV4, in neuroprotective effects. Cell culture of cortical neurons and the lactate
dehydrogenase assay was carried out. The role of receptors was discerned by using selective antagonist and ag-
onist ligands, as well as knockout (KO) PPARa mice.
Results: The ﬁndings indicate that OEA and PEA exert neuroprotective effects on cultured cortical neurons sub-
jected to a hypoxic episode. These protective effects are not mediated by the receptors, PPARa, TRPV1, or TRPV4,
because neither PPARa KO mice nor receptor ligands signiﬁcantly modify OEA and PEA-induced effects. Blocking
TRPV4 with RN1734 is neuroprotective per se, and cotreatment with OEA and PEA is able to enhance neuropro-
tective effects of the acylethanolamides. Since stimulating TRPV4 was devoid of effects on OEA and PEA-induced
protective effects, effects of RN1734 cotreatment seem to be a consequence of additive actions.
Conclusion: The lipid mediators, OEA and PEA, exert neuroprotective effects on cultured cortical neurons sub-
jected to hypoxia. Coadministration of OEA or PEA, and the TRPV4 antagonist RN1734 is able to enhance neuro-
protective effects. These in vitro results could be of utility for developing new therapeutic tools against perinatal HI.
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Introduction
Perinatal hypoxic–ischemic (HI) encephalopathy is de-
ﬁned as a neurological syndrome where the newborn suf-
fers from acute ischemia and hypoxia during the perinatal
period. Brain damage after HI insults is caused by a dele-
terious combination of glial activation, excitotoxicity, in-
ﬂammation, and oxidative stress with overproduction of
oxidative radicals, such as nitric oxide and reactive oxygen
species (ROS)1–4 The clinical relevance of this syndrome
requires further research in search for protective therapies.
Peroxisome proliferator-activated receptor subtype a
(PPARa) is a potential target for neuroprotection against
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acute ischemia and hypoxia because this receptor plays
a prominent role in the modulation of inﬂammatory
and oxidant stress responses.5–7 Thus PPARa activa-
tion is known to activate astrocytes and glial cells, to
reduce the transcription of inﬂammatory response
genes, and to promote neurological recovery by exert-
ing anti-inﬂammatory effects.8–15 Neuroprotective ef-
fects of activating PPARa are also associated with a
decrease in cerebral oxidative stress.16 In this context,
there is strong evidence that normal PPARa func-
tion is necessary to protect cells from inﬂammation
and oxidative damage in several tissues, such as
liver, heart, and spleen.17 Furthermore, PPARa ago-
nists have potentially therapeutic efﬁcacy in several
neurological diseases, such as Parkinsonism, multi-
ple sclerosis, or autoimmune encephalomyelitis.18–20
PPARa can be modulated by lipid mediators, such
as the acylethanolamides, oleoylethanolamide (OEA)
and palmitoylethanolamide (PEA). These fatty acids
act as endogenous ligands for PPARa,21–23 and sev-
eral authors have reported that OEA could exert neu-
roprotective effects through PPARa.19,24–26 Although
OEA is an analog of the endocannabinoid ananda-
mide, and PEA enhances anandamide activity, both
acylethanolamides do not act directly through cannabi-
noid (CB) receptors.21–23,27
Another family of receptors that are involved in the
response to hypoxia is the transient receptor potential
vanilloid (TRPV) family. These vanilloid receptors are
widely distributed in the central nervous system.28 It
seems that blocking the transient receptor potential
vanilloid subtype 1 or TRPV1 could mediate neuro-
protective effects, and OEA-induced neuroprotection
could be explained, in part, by its blocking effects on
TRPV1.29–32 There is also evidence showing that the
transient receptor potential vanilloid subtype 4 or
TRPV4 is involved in cerebral ischemic–reperfusion
injury, and recovery of brain edema.33–37 The TRPV4
channel induces an increase in intracellular calcium
concentration and plays an important role under
physiological and pathological conditions. Blocking
TRPV4 inhibits brain edema in cerebral ische-
mia.34,35 TRPV4 channels participate in the patho-
genic mechanisms of astroglial reactivity following
ischemic insult.38
The neuroprotectant role of OEA and PEA in brain
damage after acute hypoxia remains to be fully deter-
mined. It is worth noting that these compounds might
play a physiological role against deleterious effects of
hypoxia, because it is known that their brain levels are
increased after a traumatic or HI insult.39–41 The objec-
tives of this study were to discern: (1) the neuroprotec-
tive role of OEA and PEA in cultured cortical neurons
subjected to hypoxia, and (2) the role of PPARa,
TRPV1, and TRPV4 on possible OEA- and PEA-
mediated neuroprotective effects by using selective
receptor antagonist and agonist ligands as well as
knockout (KO) PPARa mice.
Materials and Methods
Animals
Pregnant Wistar rats (250-350 g) from the breeding
colony of the University of Seville were used. Pups at
P0 were used for in vitro experiments. Laboratory tem-
perature was kept at 22– 1C, and a 12-h light/12-h
dark cycle (lights on at 08:00 h) was maintained
throughout the experiment. Food (laboratory chow)
and water were available ad libitum.
For further studying the role of PPARa, 1-week-old
male PPARa+/+ wild-type (WT) and PPARa/ KO
mice were also used. WT and KO C57 BL/6J mice were
obtained from Jackson Laboratories (Bar Harbor, ME).
KO mice on a C57 BL/6J genetic background were
bred in accordance with European Union guidelines for
animal care. PPARa+/+ and PPARa/mice were housed
ﬁve per cage in temperature—(21– 1C) and humidity
(55– 10%)—controlled rooms with a 12-h light/12-h
dark cycle (light between 08:00 AM and 08:00 PM).
Food and water were available ad libitum during the
whole experiment. Regarding genotyping protocol for
PPARa+/+ and PPARa/ mice, it has been described
by the authors elsewhere.42
Compounds and protocol
OEA and PEA were purchased from Tocris. OEA and
PEA were dissolved in ethanol until use, and they were
used for cultures after further dilution at 10% ethanol
in Neurobasal, at doses of 0, 5, 10, 20, and 40lM. The se-
lective PPARa antagonist GW6471 or [(2S)-2-[[(1Z)-1-
Methyl-3-oxo-3-[4-(triﬂuoromethyl)phenyl]-1-propenyl]
amino]-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy-
phenylpropyl-carbamic acid ethyl ester was purchased
from Tocris, and it was dissolved in 10% dimethyl sulf-
oxide (DMSO) until use (IC50 value of GW6471 is
0.24lM). The selective antagonist of vanilloid TRPV1
SB 452533 or N-(2-Bromophenyl)-N’-[2-[ethyl(3-methyl-
phenyl)amino]ethyl]-urea was purchased from Toc-
ris, and it was dissolved in 10% DMSO until use
(pIC50 = 7.0). The selective antagonist of vanilloid
TRPV4, RN1734, or 2,4-Dichloro-N-isopropyl-N-(2-
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isopropylaminoethyl)benzene sulfonamide, was pur-
chased from Tocris (IC50 value of RN1734 is 3.2 lM
for rTRPV4). Finally, GSK1016790A, selective ago-
nist of vanilloid TRPV4, was purchased from Sigma-
Aldrich. GSK1016790A or (N-((1S)-1-{[4-((2S)-2-{[(2,
4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypro-
panoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-
benzothiophene-2-carboxamide) is known to evoke a
dose-dependent activation of TRPV4 whole-cell cur-
rents at concentrations above 1 nM.
Cell culture and lactate dehydrogenase assay
Primary cultures of parietotemporal cortical neuronswere
established as previously described,43 with some modiﬁ-
cations suggested by others.44,45 The cell suspension
was adjusted at *30,000 cells per well in all tests.
Postnatal rat pups (P0) or 1-month-old PPAR-a + / +
and PPAR-a/ mice were killed by decapitation, and
brains were removed. All animals were humanely
sacriﬁced.
Exposure to pharmacological compounds and hyp-
oxia was initiated after 4 days of in vitro conditions.45
Treatments were carried out either before or after hyp-
oxia exposure. Regarding experiments before hypoxia,
OEA and PEA were added to the culture medium for
30min, at different concentrations (0, 5, 10, 20, and
40lM, all compounds). If selective receptor ligands
were used (GW6471, SB 452533, RN1734), they were
added to the medium 15min before OEA and PEA.
SB 452533 and RN1734 were used at doses of 0, 0.1, 1,
5, and 10lM. GSK1016790A was used at doses of 1
and 5 nM. In these cases, acylethanolamides were used
at the most effective dose, or not added for studying
per se effects of antagonists. Thereafter, neurons were ex-
posed during 40min to hypoxia by using hypoxic me-
dium, consisting of Neurobasal without B27, which
had been exposed to 95% N2/5% CO2 air bubbling for
30min. After this 40-min hypoxia period, the medium
was replaced with fresh incubation solution equili-
brated with 95% O2/5% CO2. As regards experiments
after hypoxia, the protocol was similar but Neurobasal
without B27 was used as the incubation solution equil-
ibrated with 95% O2/5% CO2, and OEA and PEA were
added to the medium for 30min just after the 40-min
hypoxia exposure (antagonists were not used). Times
of 30-min incubation of OEA and PEA and 40min of
hypoxia exposure were selected after pilot studies.
Thus 30-min incubation was selected because shorter
incubation was less effective, and longer incubation
did not further modify OEA and PEA-induced effects
(data not shown). Forty minutes of hypoxia was se-
lected because it induces 55–65% cell death in cultured
cells of rat pups, and 75–85% cell death in cultured
cells of mice. These percent values allow better discern-
ing protective effects, because lower values (20 and
30min of hypoxia) induced lower cell death with
higher data variability, and highest values (50 and
60min of hypoxia) induced strong cell death (data
available on request).
After all treatments, the medium was removed, and
the cultures were further incubated for 24 h, to carry
out the lactate dehydrogenase (LDH) assay.19 Cyto-
toxicity was evaluated by release of the cytosolic en-
zyme LDH into the culture medium by dying cells
(Cytotoxicity Detection Kit; Roche, Indianapolis,
IN). Total LDH release or high control was calculated
by incubating untreated cells with 0.5% Triton X-100
for 1 h to induce maximal cell lysis. Basal death or low
control was calculated from untreated wells with
media without B27. Background LDH release was
calculated with media alone without cells and the ab-
sorbance value obtained from this background con-
trol is subtracted from all other absorbance values.
The formula of percent cell death was as follows: Per-
cent cell death = [(experimental value-low control)/
(high control-low control] · 100. Data are given as per-
cent cell survival, which is calculated as (100—percent
cell death).
Statistics and ethics
For statistics, two-way analysis of variance (ANOVA)
and post hoc tests (one-way ANOVA, Newman–Keuls)
were used for statistical comparisons. Regarding OEA
and PEA effects on cell survival, two-way ANOVA
was used with lipid concentration (0–40lM) and time
of treatment with respect to hypoxia as factors. As
regards KOmice, the two variables were lipid concentra-
tion (0–40lM) and genotyping (KO, WT). Finally,
when receptor ligands were used, the two factors
were lipid coincubation (no, OEA, PEA) and receptor
ligand concentration. Experiments were performed
according to the animal care guidelines of the Euro-
pean Communities Council (86/609/ECC, 90/679/
ECC, 98/81/CEE, 2003/65/EC, Commission Recom-
mendation 2007/526/EC), European Directive 2010/
63/EU, and the Spanish Royal Decree 53/2013 on the
protection of animals used for research and other sci-
entiﬁc purposes. Animal experiments were approved
by the local Ethics Committee (CEEA; University of
Seville, BIO127).




OEA exerts neuroprotection if given either
before or after hypoxia
Two-way ANOVA revealed a dose effect after OEA treat-
ment (F4, 70= 11.7, p< 0.001), without interaction. Thus,
OEA given either before or after hypoxia exerted similar
effects. One-way ANOVA revealed a signiﬁcant dose ef-
fect after OEA treatment before hypoxia exposure (F4,
44= 5.6, p< 0.01), 20 and 40lMOEA reliably enhancing
cell survival relative to 0 dose-treated cells (20lMOEA,
p< 0.05; 40lMOEA, p< 0.01; Newman–Keuls). If OEA
was given after hypoxia, one-way ANOVA revealed a
signiﬁcant dose effect (F4, 39= 8.9, p< 0.01), and post
hoc analysis indicated that 40lMOEA exerted a neuro-
protective effect ( p< 0.01, Newman–Keuls), as shown in
Figure 1.
PEA exerts neuroprotection if given either
before or after hypoxia
Two-way ANOVA revealed a dose effect after PEA treat-
ment (F4, 70= 12.6, p< 0.001), without interaction. Thus
PEA given either before or after hypoxia exerted similar
effects. One-way ANOVA revealed a signiﬁcant dose ef-
fect after PEA treatment before hypoxia exposure (F4,
44= 17.3, p< 0.001). Thus 10, 20, and 40lMPEA reliably
enhanced cell survival relative to 0 dose-treated cells
(10lM PEA, p< 0.05; 20lM and 40lM PEA, p< 0.01;
Newman–Keuls). If PEA was given after hypoxia, similar
changes were found (dose effect, F4, 39 = 3.2; p < 0.02;
10, 20 and 40lM PEA, p< 0.01; Newman–Keuls), as
shown in Figure 2.
Neuroprotective properties of OEA and PEA
are not mediated by PPARa receptors
As explained, to block PPARa, the selective antagonist
GW6471 was added to the culture medium. Following
GW6471 administration, the survival effects of 40lM
OEA or PEA before hypoxia episode were not signiﬁ-
cantly modiﬁed, as shown in Table 1.
Furthermore, after using PPARa/ mice, the neuro-
protective effects of OEA and PEA remain, without sig-
niﬁcant differences between both groups, as shown in
Figure 3. Two-way ANOVA revealed dose effects with-
out interaction for every compound (OEA, F4,
50 = 155, p < 0.001; PEA, F4, 50 = 69, p < 0.001).
Regarding OEA, one-way ANOVA revealed a signiﬁ-
cant dose effect after OEA treatment before hypoxia
exposure (PPARa/ mice, F4, 29= 72, p < 0.001; WT
mice, F4, 29 = 83.3, p < 0.001), and 10, 20, and 40lM
OEA were observed to signiﬁcantly enhance cell sur-
vival relative to 0 dose-treated cells in both types of
cells (10 lM OEA, p < 0.05; 20lM OEA, p< 0.01;
40 lM OEA, p< 0.01; Newman–Keuls). As regards
PEA, one-way ANOVA revealed a signiﬁcant dose effect
after PEA treatment before hypoxia exposure (PPARa/
mice, F4, 29= 33.9, p< 0.001; WT mice, F4, 29= 35,
FIG. 1. Percent cell survival of cortical neurons after OEA given before and after hypoxia episode.
Mean – SEM. *p < 0.05, **p < 0.01 versus corresponding 0 dose (Newman–Keuls). OEA, oleoylethanolamide;
SEM, standard error of the mean.
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p < 0.001). Thus 10, 20, and 40lM PEA reliably en-
hanced cell survival relative to 0 dose-treated cells in
both types of cells (10 lM PEA, p< 0.05; 20lM and
40 lM PEA, p< 0.01; Newman–Keuls). Cultured cells
of mice seem to better respond to OEA and PEA
than those of rats, since 40 lM OEA and PEA en-
hanced percent cell survival by 75% in cultured neu-
rons of mice, whereas this value was *50% in
cultured cells of rat pups.
Neuroprotective properties of OEA and PEA
are not mediated by TRPV1
The selective antagonist SB 452533 was given for block-
ing TRPV1. Following SB 452533 at different doses and
40lM OEA or PEA, two-way ANOVA did not reveal
signiﬁcant effects, as shown in Table 2.
Neuroprotective properties of OEA and PEA
are not mediated by TRPV4, and TRPV4 blocking
is neuroprotective per se
First, the selective agonist GSK1016790A was added to
the medium for stimulating TRPV4. GSK1016790A was
found to induce full cell death at doses higher than
10nM (data not shown). Since lower doses induced less
cell death, as shown in Table 3, 0, 1, and 5nM
GSK1016790A was used. Following GSK1016790A at 1
and 5nM, one-way ANOVA revealed a signiﬁcant dose
effect on cell death (F2, 19=12.9, p< 0.05), as shown in
Table 3, because GSK1016790A induced cell death per
se. Regarding OEA and PEA cotreatment, two-way
ANOVA did not reveal interaction or dose effects, be-
cause 40lM OEA or PEA did not induce signiﬁcant
changes in cell death after coadministration with
GSK1016790A. Hence, the survival effects of 40lM
OEA or PEA before the hypoxia episode were not signif-
icantly modiﬁed after GSK1016790A, as shown in
Table 3, although this drug induced cell death per se, at
all the concentrations tested.
Second, the selective antagonist RN1734 was added to
the medium for blocking TRPV4. RN1734 was neuro-
protectant per se, as revealed by one-way ANOVA
FIG. 2. Percent cell survival of cortical neurons after PEA given before and after hypoxia episode. Mean – SEM.
*p < 0.05, **p < 0.01 versus corresponding 0 dose (Newman–Keuls). PEA, palmitoylethanolamide.
Table 1. Percent Cell Survival Effects of 40 lM
Oleoylethanolamide and Palmitoylethanolamide
After Adding GW6471, Selective Peroxisome
Proliferator-Activated Receptors Subtype a Antagonist
40 lM OEA 40lM PEA GW6471 alone GW6471 dose (lM)
94.1– 3 94.5– 3 34.3– 3 0
93.3– 4 93.6– 2 36.1– 2 0.1
91.4– 2 95.4– 4 37.2– 4 1
95.2– 3 95.3– 2 38.3– 3 5
93.4– 2 96.2– 1 38.4– 4 10
Mean– SEM. Compounds were added to culture media before hyp-
oxia episode.
OEA, oleoylethanolamide; PEA, palmitoylethanolamide; SEM, standard
error of the mean.
Portavella, et al.; Cannabis and Cannabinoid Research 2018, 3.1
http://online.liebertpub.com/doi/10.1089/can.2018.0013
175
(F4, 24= 19.1, p< 0.05). Thus, the highest RN1734 doses
(5 and 10lM) signiﬁcantly reduced cell death, as shown
in Table 3 ( p< 0.05 vs. the remainder doses, Newman–
Keuls). Regarding OEA and PEA cotreatment, two-way
ANOVA did not reveal interaction or dose effects. How-
ever, following RN1734 at different doses and 40lM
OEA, one-way ANOVA revealed a signiﬁcant dose ef-
fect (F4, 24= 24.5, p< 0.05), as shown in Table 3. The
highest RN1734 dose (10lM) signiﬁcantly enhanced
neuroprotective effects of 40lM OEA ( p< 0.05 vs. the
remainder doses, Newman–Keuls). As regards
RN1734 at different doses and 40lM PEA, one-way
ANOVA revealed a signiﬁcant dose effect (F4,
24= 25.2, p< 0.05). Thus, the highest RN1734 doses (5
and 10lM) signiﬁcantly enhanced neuroprotective ef-
fects of 40lM PEA, as shown in Table 3 ( p< 0.05 vs.
the remainder doses, Newman–Keuls). Thus, neuropro-
tective properties of OEA and PEA seem to be enhanced
after blocking TRPV4 (Table 3). Since stimulating
TRPV4 was devoid of effects on OEA and PEA protec-
tive effects, effects of RN1734 cotreatment seem to be a
consequence of additive actions.
Discussion
Brain damage after HI insults is caused by the deleteri-
ous combination of glial activation, excitotoxicity, in-
ﬂammation, and oxidative stress with overproduction
of ROS.1–4 We have tested in a culturing cell model
of neuronal hypoxia some lipid mediators that are
known to act through receptors, which are otherwise
involved in post-HI reactions. These receptors encom-
pass PPARa, and the vanilloid receptors TRPV1 and
TRPV4. These lipid mediators belong to the family of
acylethanolamides, which are CB derivatives that do
not act through CB receptors.21–23,27
FIG. 3. Percent cell survival of cortical neurons after OEA and PEA in PPARa+/+ WT and PPARa/ KO mice. All
compounds were given before hypoxia episode. Mean – SEM. *p < 0.05, **p < 0.01 versus corresponding 0 dose
(Newman–Keuls). KO, knockout; PPARa, peroxisome proliferator-activated receptors subtype a; WT, wild-type.
Table 2. Percent Cell Survival Effects of 40 lM
Oleoylethanolamide and Palmitoylethanolamide
After Blocking Transient Receptor Potential Vanilloid
Subtype 1 with SB 452533
40lM OEA 40 lM PEA SB 45253 alone SB 452533 dose (lM)
95.2– 5 95– 3 52.8– 4 0
94.4– 3 98.1– 5 52.6– 5 0.1
98.7– 4 97.8– 2 51.8– 5 1
97 – 5 96.3– 2 52– 5 5
93 – 4 95.6– 2 54.3– 4 10
Mean– SEM. All compounds were given before hypoxia.
Table 3. Percent Cell Survival Effects of 40lM
Oleoylethanolamide and Palmitoylethanolamide After
Stimulating or Blocking Transient Receptor Potential Vanilloid
Subtype 4 with GSK1016790A or RN1734, Respectively
Stimulating TRPV4
40lM OEA 40 lM PEA GSK1016790A alone GSK1016790A (nM)
92.8– 4 2.2– 3 45.4– 6 0
91.2– 4 94.1– 3 33.4– 4* 1
93.3– 3 92– 3 31.5– 5* 5
Blocking TRPV4
40lM OEA 40 lM PEA RN1734 alone RN1734 dose (lM)
92.1– 3 93.8– 4 47.4– 5 0
91.2– 4 97.1– 3 48.3– 5 0.1
94.3– 4 97– 3 55.4– 4 1
98– 1 100# 64.4– 3^ 5
100# 100# 65.5– 5^ 10
Mean– SEM. All compounds were given before the hypoxia episode.
*p< 0.05 versus corresponding 0 dose of GSK1016790A alone
(Newman–Keuls).
#p < 0.05 versus corresponding 0 and 0.1 dose of RN1734 + OEA/PEA
(Newman–Keuls).
^p< 0.05 versus corresponding 0 and 0.1 dose of RN1734 alone
(Newman–Keuls).
TRPV4, transient receptor potential vanilloid subtype 4.
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The ﬁndings of the present study indicate that the
fatty acid acylethanolamides, OEA and PEA, exert neu-
roprotective effects on cultured parietotemporal corti-
cal neurons subjected to a hypoxic episode. These
effects are dose dependent, the 40lM OEA/PEA dose
exerting the strongest neuroprotective effects. Contrary
to expectation, these effects are not mediated by
PPARa, TRPV1, or TRPV4. In this context, these
fatty acids exert neuroprotective effects in other cellular
and animal models through these receptors,21–23,29,30
and OEA and PEA act as endogenous ligands for
PPARa, exerting neuroprotective effects.19–24,26 OEA
is also known to act as a neuroprotectant through the
TRPV1 in other situations.31,32 To sum up, neuropro-
tective effects on cortical neurons against acute hypoxia
are mediated by mechanisms other than PPARa or
vanilloid receptors, TRPV1 or TRPV4.
Interestingly, blocking TRPV4 is neuroprotective per
se. The neuroprotective role of TRPV4 in ischemia epi-
sodes has been highlighted recently, because TRPV4 is
involved in cerebral ischemic–reperfusion injury and re-
covery of brain edema.33,34 Stimulation of TRPV4 is ob-
served to be cytotoxic per se for cultured cortical neurons,
as expected since the activation of TRPV4 is known to
induce cytotoxicity in many types of cells.34–37
It is of note that TRPV4 blocking reliably enhances the
neuroprotective effects of OEA and PEA. Since TRPV4
activation is devoid of effects on neuroprotection of
both acylethanolamides, the ﬁndings after TRPV4 block-
ing could be accounted for by additive actions rather than
pharmacodynamic interactions between coadministered
drugs. It is worth noting that a complete protection
against hypoxia of cortical neurons is afforded by high
doses of the TRPV4 antagonist RN1734 when it is coad-
ministered with 40lMOEA or PEA. The additive action
of TRPV4 blocking could be explained by diverse mech-
anisms. Thus, TRPV4 channels participate in changes in
intracellular calcium concentration and astroglial reac-
tivity, and TRPV4 are upregulated during cerebral ische-
mia.34–36,38 TRPV4 is also known to be sensitive to cell
swelling and arachidonic acid and its metabolites,
which are associated with cerebral ischemia.35 These
hypoxia-induced deleterious effects might be further at-
tenuated after blocking vanilloid TRPV4. Finally,
TRPV4 blocking inhibits brain edema in cerebral ische-
mia, and reactive astrocytosis after stroke.34,37
The results of the present studypoint tonew therapeutic
approaches for ﬁghting cortical neuron death after a hyp-
oxia episode, because treatment with the lipids OEA and
PEA or cotreatment with these acylethanolamides and
TRPV4 antagonists might be pharmacological tools with
protective effects in vivo as do they in vitro.
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ROS¼ reactive oxygen species
TRPV¼ transient receptor potential vanilloid
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